Holen Sie sich die Stockscreener-App
3.34
3.41%
0.11
Handel nachbörslich:
3.41
0.07
+2.10%
Schlusskurs vom Vortag:
$3.23
Offen:
$3.25
24-Stunden-Volumen:
21,120
Relative Volume:
0.43
Marktkapitalisierung:
$10.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.29M
KGV:
-0.1371
EPS:
-24.3686
Netto-Cashflow:
$-6.81M
1W Leistung:
-8.24%
1M Leistung:
+17.19%
6M Leistung:
-15.23%
1J Leistung:
+4.05%
1-Tages-Spanne:
$3.15
$3.41
1-Wochen-Bereich:
$3.15
$3.69
52-Wochen-Spanne:
$2.01
$6.47
Heartsciences Inc Stock (HSCS) Company Profile
Firmenname
Heartsciences Inc
Sektor
Branche
Telefon
682-237-7781
Adresse
550 RESERVE ST, SUITE 360, SOUTHLAKE
Vergleichen Sie HSCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HSCS
Heartsciences Inc
|
3.34 | 10.27M | 0 | -7.29M | -6.81M | -24.37 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Heartsciences Inc Aktie (HSCS) Neueste Nachrichten
Panic Selling: Can HeartSciences Inc Equity Warrant sustain its profitabilityWeekly Profit Analysis & Safe Capital Growth Tips - baoquankhu1.vn
Growth Value: Will Investors Title Company outperform the market in YEARForecast Cut & Short-Term High Return Ideas - baoquankhu1.vn
Risks Report: Can HeartSciences Inc Equity Warrant ride the EV waveJuly 2025 Snapshot & Weekly High Momentum Picks - baoquankhu1.vn
Trend Review: Is HeartSciences Inc Equity Warrant attractive for institutional investorsJuly 2025 News Drivers & Fast Gain Swing Trade Alerts - baoquankhu1.vn
HeartSciences Secures New Private Financing Through Note Issuance - TipRanks
HeartSciences Signs Note Purchase Agreement With Streeterville Capital - TradingView
Trend Report: How HeartSciences Inc Equity Warrant stock reacts to oil pricesJuly 2025 Reactions & Real-Time Chart Breakout Alerts - Bộ Nội Vụ
Will HeartSciences Inc. Equity Warrant stock recover faster than peersJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - Улправда
Why hedge funds are buying HeartSciences Inc. Equity Warrant stockWeekly Profit Report & Fast Momentum Stock Entry Tips - Улправда
What hedge fund activity signals for HeartSciences Inc. Equity Warrant stockJuly 2025 Chart Watch & Verified Stock Trade Ideas - Улправда
Why HeartSciences Inc. Equity Warrant stock remains resilientMarket Performance Recap & High Return Trade Opportunity Guides - ulpravda.ru
Why HeartSciences Inc. Equity Warrant stock appeals to dividend seekersJuly 2025 News Drivers & Scalable Portfolio Growth Methods - ulpravda.ru
Can HeartSciences Inc. stock deliver sustainable ROEWeekly Earnings Recap & Growth Focused Entry Point Reports - Улправда
Will HeartSciences Inc. stock recover faster than peers2025 Sector Review & Momentum Based Trading Signals - Улправда
Is HeartSciences Inc. stock a safe haven asset2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Buyout Rumor: Why HeartSciences Inc. Equity Warrant stock remains resilientJuly 2025 Chart Watch & High Conviction Buy Zone Picks - ulpravda.ru
Published on: 2026-01-12 22:13:00 - ulpravda.ru
Is HeartSciences Inc. Equity Warrant stock supported by strong cash flows2026 world cup usa national team group stage defensive leaders transition play odds analysis expert opinion - ulpravda.ru
What analysts say about HeartSciences Inc Equity Warrant stockMarket Depth Overview & Free Technical Analysis and Insights - Early Times
Market Meltdown the Virus and our ActionablesStock Price Divergence & Affordable Trading Strategies - bollywoodhelpline.com
Going all in on OTM options with low probabilities.Price Support Zones & Access Powerful Market Insights - bollywoodhelpline.com
Indo Count Industries Limited (ICIL) Expands into New MarketPrice-to-Book Ratio Updates & Exceptional Capital Growth - bollywoodhelpline.com
HeartSciences (NASDAQ:HSCS) Price Target Raised to $9.20 at Ascendiant Capital Markets - Defense World
HeartSciences (NASDAQ:HSCS) and Movano (NASDAQ:MOVE) Critical Survey - Defense World
Ascendiant Capital Maintains HeartSciences (HSCS) Buy Recommendation - Nasdaq
HeartSciences (HSCS) Receives Updated Analyst Rating and Price T - GuruFocus
HeartSciences (NASDAQ:HSCS) & Health Catalyst (NASDAQ:HCAT) Critical Analysis - Defense World
Does HeartSciences Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
Is HeartSciences Inc. Equity Warrant stock a top pick in earnings seasonEarnings Recap Report & Low Risk High Reward Ideas - Улправда
Why HeartSciences Inc. Equity Warrant stock could see breakout soon2025 Sector Review & Fast Entry High Yield Tips - Улправда
Will HeartSciences Inc. Equity Warrant stock attract ESG investorsMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
Will HeartSciences Inc. Equity Warrant stock deliver shareholder valueJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
History Review: Does HeartSciences Inc. stock trade at a discount to peers2025 Major Catalysts & Real-Time Volume Triggers - Улправда
HeartSciences Submits MyoVista wavECG Device for FDA Clearance - Diagnostic and Interventional Cardiology
HeartSciences approves indemnification agreements for directors and officers By Investing.com - Investing.com Nigeria
HeartSciences approves indemnification agreements for directors and officers - Investing.com
Heart Test Laboratories Approves Indemnification Agreement - TipRanks
HeartSciences reports no meaningful revenue in Q2 2026 - Medical Buyer
HeartSciences Inc. Reports Second Quarter Fiscal 2026 Financial Results and Progress on MyoVista Insights and wavECG Device Submissions - Quiver Quantitative
HeartSciences (Nasdaq: HSCS) Q2 shows $2M cash, MyoVista Insights push - Stock Titan
HeartSciences (NASDAQ: HSCS) posts loss, highlights going concern and new funding - Stock Titan
HeartSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025 - marketscreener.com
HeartSciences files FDA 510(k) for MyoVista WaveCG device - marketscreener.com
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - The Manila Times
HeartSciences (Nasdaq: HSCS) separates device, AI-ECG FDA paths - Stock Titan
HeartSciences Inc. Announces Commercial Release of MyoVista Insights™ Version 1.1 Enhancing ECG System Capabilities - Quiver Quantitative
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with ... - Enidnews.com
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 - The Manila Times
HeartSciences Announces Major Upgrade to User Features of - GlobeNewswire
Gross profit of HeartSciences Inc. from 2021 to 2024 - Statista
Finanzdaten der Heartsciences Inc-Aktie (HSCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):